Childhood Cancer Data Initiative Annual Symposium (Abstract Registration): Submission #41

Submission information
Submission Number: 41
Submission ID: 148393
Submission UUID: 0152f5c9-da71-4180-9908-037cc01084ed

Created: Thu, 08/07/2025 - 13:55
Completed: Thu, 08/07/2025 - 14:24
Changed: Thu, 08/07/2025 - 14:24

Remote IP address: 10.208.28.64
Submitted by: Anonymous
Language: English

Is draft: No
Abstract Title: Pediatric PRISSMM model for real world medical record data to capture stage, treatment and cancer outcomes
Abstract: Background: Approaches to obtaining structured clinical oncology data from the medical record are not standardized. PRISSMM was developed to reliably and reproducibly capture real-world oncology clinical data for adult solid malignancies from the medical record. We adapted the PRISSMM method to pediatric solid tumors(pediPRISSM) and assessed the feasibility of using pediPRISSMM to determine stage at presentation and progression-free survival(PFS) in patients with Ewing sarcoma(EWS). Methods: Patients diagnosed with EWS who had tumor molecular profiling had medical records abstracted using pediPRISSMM at two institutions. Staging was derived from disease site information from imaging performed during staging (4 weeks from diagnosis). PFS from the diagnosis was based on disease status from radiology reports(PFSimaging) and chemotherapy drug regimen start and stop dates(PFSdrugs). Results: 158 patients with a confirmed EWS-associated fusion were included. Median age at diagnosis was 17 years (range of 1-75), 63% were male and 80% had primary bone disease. Currently, complete pediPRISSM data are available for 43 patients. It was possible to derive stage from pediPRISSMM radiology data for 63% of patients. PFSimaging and PFSdrugs were concordant in 74% of patients. Medical record review for patients with a difference of >6 weeks in PFS revealed multi-institutional care as the most common reason for discordance. Conclusions: Although further analysis is ongoing, these data support the universal implementation of accurate staging forms as part of routine clinical documentation. Concordant findings using PFSimaging and PFSdrugs were achieved in the majority of patients, with highest success seen in patients treated at single institutions.
Abstract:
Authors:
  1. First Name: Sidney
    Middle Initial: N
    Last Name: Benich
    Degree(s): M.S.
    Organization: Dana-Farber Cancer Institute
  2. First Name: Stephanie
    Last Name: Suser
    Degree(s): B.A.
    Organization: Memorial Sloan Kettering Cancer Center
  3. First Name: Evelina
    Last Name: Ceca
    Degree(s): MBA
    Organization: Dana-Farber Cancer Institute
  4. First Name: Liliana
    Last Name: Rodriguez
    Organization: Memorial Sloan Kettering Cancer Center
  5. First Name: Madhumitha
    Last Name: Sridharan
    Degree(s): B.E.
    Organization: Dana-Farber Cancer Institute
  6. First Name: Julian
    Last Name: Schwartz
    Degree(s): B.S.
    Organization: Memorial Sloan Kettering Cancer Center
  7. First Name: Zachary
    Last Name: Kahn
    Degree(s): B.S.
    Organization: Dana-Farber Cancer Institute
  8. First Name: Anita
    Last Name: Bowman
    Degree(s): M.S.
    Organization: Memorial Sloan Kettering Cancer Center
  9. First Name: Joseph
    Last Name: White
    Degree(s): Ph.D.
    Organization: Dana-Farber Cancer Institute
  10. First Name: Rose
    Last Name: Brannon
    Degree(s): Ph.D.
    Organization: Memorial Sloan Kettering Cancer Center
  11. First Name: Wendy
    Middle Initial: B
    Last Name: London
    Degree(s): Ph.D.
    Organization: Dana-Farber Cancer Institute
  12. First Name: Neerav
    Middle Initial: N
    Last Name: Shukla
    Degree(s): M.D.
    Organization: Memorial Sloan Kettering Cancer Center
  13. First Name: Katherine
    Middle Initial: A
    Last Name: Janeway
    Degree(s): M.D., MMSc
    Organization: Dana-Farber Cancer Institute
Presenting Author: Sidney Benich
Institution: Dana-Farber Cancer Institute
Email Address: sidneyn_benich@dfci.harvard.edu